Pacific Biosciences of California, Inc. (PACB)

From the record

Pacific Biosciences of California, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Pacific Biosciences of California, Inc.'s 10 filed years say what it did: revenue went from $91 million in fiscal 2016 to $160 million in fiscal 2025, up 6.5% a year; it rose in 5 of 9 years; the deepest fall was 23% from fiscal 2023 to fiscal 2024; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pacific Biosciences of California, Inc. lost about 10215 cents for every dollar of shareholders' money, and gross profitability: its products earned about 6 cents per dollar of everything the company owns. Leverage: it owed about 99 cents per dollar of assets, and net share issuance: its share count grew 4.0% over the year (the filed statements).

From the record

Pacific Biosciences of California, Inc.'s standing among 21 graded names in its industry family: revenue of $160 million in fiscal 2025 ranks in the top 50% by size; a net margin of -341.5% ranks in the bottom 17%; revenue growth of 7.6% a year over the last 3 filed years ranks in the top 22% (its annual reports).

From the record

Pacific Biosciences of California, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Van, Oene Mark (President & CEO, as filed), filing under that title since 2026-08-11, 3 months (bottom 8% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 7.1 years (top 17%); 18 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Pacific Biosciences of California, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $64 million against no long-term debt tagged leaves 8.1% of its assets as net cash, top 43% of its family; cash from operations less capital spending is -71.2% of revenue (bottom 31%); a gross margin of 28.6% (bottom 8%); research spending of 60.8% of revenue (top 17%) (its annual report).

From the record

Pacific Biosciences of California, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 7.6% a year over the last three filed years against 6.5% over all 10, speeding up (top 17% of its family); the newest year grew 3.9% (top 40%); research spending grew -20.4% a year (bottom 8%); capital spending grew -45.5% a year (bottom 18%) (its annual reports). Pacific Biosciences of California, Inc. reported 3 product lines in fiscal 2025: Consumable at $82 million (51%), Instrument at $54 million (34%), Service and Other at $24 million (15%); 2 of 3 grew against the year before (its annual report).

From the record

Pacific Biosciences of California, Inc.'s newest year against its own record: revenue of $160 million in fiscal 2025 came in 5.2% below the $169 million its prior three years' pace pointed to (bottom 43% of its family); net income of $546 million against a prior three-year average of $310 million (bottom 33%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 13%) (its annual reports).